OBJECTIVE: Septic complications and the emergence of drug-resistant microbes represent serious risks to patients. Recently, naturally occurring peptides have been discovered that possess potent and broad-spectrum antimicrobial activity. Protegrin-1 is particularly attractive for clinical use in human wounds because, unlike defensins, protegrin-1 retains broad antimicrobial and antifungal activity at physiologic salt concentration and in the presence of serum. The objective of this study was to examine the efficacy of protegrin-1 in killing multiple drug-resistant microbes isolated from human burn patients. DESIGN: For thein vitroexperiment, bilayer radial diffusion was performed comparing standard antibiotics with protegrin-1 on multiple-drug-resistant microbial organisms isolated from infected burn wounds. In vivo, rats received a 20% total body surface area partial-thickness burn by immersion in 60 degrees C water for 20 secs followed by wound seeding with 106 colony forming units of Silvadene-resistant Pseudomonas aeruginosa. SETTING: University of Michigan research laboratory. SUBJECTS: Adult, male Sprague-Dawley rats. INTERVENTIONS: Rats were randomized into three groups: those receiving synthetic protegrin-1, acetic acid (carrier), or gentamicin (positive control). Protegrin-1 was administered by topical application or intradermal injection. Wound tissues were harvested aseptically at different time points for quantitative bacterial counts. MEASUREMENTS AND MAIN RESULTS: In vivo and in vitro experiments revealed rapid and significant decreases in bacterial counts for protegrin-1-treated groups compared with controls. CONCLUSIONS: This study shows that protegrin-1 potentially may be used as an alternative or adjunct therapy to standard agents used to treat wound infections.
OBJECTIVE: Septic complications and the emergence of drug-resistant microbes represent serious risks to patients. Recently, naturally occurring peptides have been discovered that possess potent and broad-spectrum antimicrobial activity. Protegrin-1 is particularly attractive for clinical use in human wounds because, unlike defensins, protegrin-1 retains broad antimicrobial and antifungal activity at physiologic salt concentration and in the presence of serum. The objective of this study was to examine the efficacy of protegrin-1 in killing multiple drug-resistant microbes isolated from human burn patients. DESIGN: For thein vitroexperiment, bilayer radial diffusion was performed comparing standard antibiotics with protegrin-1 on multiple-drug-resistant microbial organisms isolated from infected burn wounds. In vivo, rats received a 20% total body surface area partial-thickness burn by immersion in 60 degrees C water for 20 secs followed by wound seeding with 106 colony forming units of Silvadene-resistant Pseudomonas aeruginosa. SETTING: University of Michigan research laboratory. SUBJECTS: Adult, male Sprague-Dawley rats. INTERVENTIONS:Rats were randomized into three groups: those receiving synthetic protegrin-1, acetic acid (carrier), or gentamicin (positive control). Protegrin-1 was administered by topical application or intradermal injection. Wound tissues were harvested aseptically at different time points for quantitative bacterial counts. MEASUREMENTS AND MAIN RESULTS: In vivo and in vitro experiments revealed rapid and significant decreases in bacterial counts for protegrin-1-treated groups compared with controls. CONCLUSIONS: This study shows that protegrin-1 potentially may be used as an alternative or adjunct therapy to standard agents used to treat wound infections.
Authors: Lars Steinstraesser; Till Koehler; Frank Jacobsen; Adrien Daigeler; Ole Goertz; Stefan Langer; Marco Kesting; Hans Steinau; Elof Eriksson; Tobias Hirsch Journal: Mol Med Date: 2008 Jul-Aug Impact factor: 6.354
Authors: Mark W Lisanby; Melissa K Swiecki; Brian L P Dizon; Kathryn J Pflughoeft; Theresa M Koehler; John F Kearney Journal: J Immunol Date: 2008-10-01 Impact factor: 5.422
Authors: Tianhong Dai; Gitika B Kharkwal; Masamitsu Tanaka; Ying-Ying Huang; Vida J Bil de Arce; Michael R Hamblin Journal: Virulence Date: 2011-07-01 Impact factor: 5.882
Authors: Mark R Hemmila; Aladdein Mattar; Michael A Taddonio; Saman Arbabi; Tarek Hamouda; Peter A Ward; Stewart C Wang; James R Baker Journal: Surgery Date: 2010-03-02 Impact factor: 3.982
Authors: Elaine G Rodrigues; Andrey Ss Dobroff; Clarissa F Cavarsan; Thaysa Paschoalin; Leonardo Nimrichter; Renato A Mortara; Edson Lucas Santos; Marcos A Fázio; Antonio Miranda; Sirlei Daffre; Luiz R Travassos Journal: Neoplasia Date: 2008-01 Impact factor: 5.715
Authors: Angela L Gibson; Christina L Thomas-Virnig; John M Centanni; Sandy J Schlosser; Colette E Johnston; Kelly F Van Winkle; Andrea Szilagyi; Li-Ke He; Ravi Shankar; B Lynn Allen-Hoffmann Journal: Wound Repair Regen Date: 2012 May-Jun Impact factor: 3.617